InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

This article is part of “Innovations In: Kidney Disease,” an editorially independent special report that was produced with financial support from Vertex. There is also good news for hopeful parents.

Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that ...

Editor’s note: If you or someone you know is struggling with mental health, help is available. Dial or text 988 or visit 988lifeline.org for free and confidential support. Summer passed Valerie Zeko ...

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA regulatory pathway to commercialize treatments for rare diseases. Last February ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...

A new experimental scalp treatment called clascoterone has shown strong results in helping reduce male-pattern hair loss (also known as androgenetic alopecia, or AGA). Experts call the results ...

Treatment of chronic lymphocytic leukemia (CLL) currently consists of two main approaches — continuous therapy with Bruton’s tyrosine kinase inhibitors and fixed-duration regimens combining venetoclax ...

Former President Joe Biden is undergoing a new phase of treatment for an aggressive form of cancer that was diagnosed in May, a spokesperson said Saturday. Subscribe to read this story ad-free Get ...

Victor Sung, M.D., director of the Division of Movement Disorders in the University of Alabama at Birmingham Department of Neurology and director of the UAB Huntington’s Disease Clinic, reacted to the ...